Lithocholic Acid

Lithocholic Acid

SCHEMBL23923735

CC(CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 7/20 1.00
EPHA2 P29317 4/20 1.00
CASP7 P55210 3/20 1.00
VDR P11473 3/20 1.00
HIF1A Q16665 3/20 1.00
TP53 P04637 2/20 1.00
MAPK1 P28482 2/20 1.00
HSD17B10 Q99714 2/20 1.00
BLM P54132 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
USP2 O75604 2/20 1.00
CYP3A4 P08684 2/20 1.00
NR1H4 Q96RI1 2/20 1.00
LMNA P02545 2/20 1.00
MDM4 O15151 1/20 1.00
MAPT P10636 1/20 1.00
HSPD1 P10809 1/20 1.00
TSHR P16473 1/20 1.00
PTPN2 P17706 1/20 1.00
PTPN1 P18031 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithocholic Acid SCHEMBL22756077 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL22894393 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL22871939 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL22079173 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL24001494 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL22894425 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL24001453 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL24567422 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL22415871 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A
Lithocholic Acid SCHEMBL21841344 1.00 GPBAR1 (1.00) GPBAR1EPHA2CASP7VDRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023068376-A1 PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT 国立大学法人九州大学 2023-04-27 WO claimed
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
WO-2023205801-A2 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics (US) 2023-10-26 WO disclosed
WO-2023068376-A1 PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT 国立大学法人九州大学 2023-04-27 WO disclosed
US-20210323995-A1 ISOLITHOCHOLIC ACID OR ISOALLOLITHOCHOLIC ACID AND DEUTERATED DERIVATIVES THEREOF FOR PREVENTING AND TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES PHENEX PHARMACEUTICALS AG (DE) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers SREBF1, SREBF2, NR1H3 GPBAR1 138/4885EPHA2 1690/4885CASP7 1115/4885
US-20210323995-A1 ISOLITHOCHOLIC ACID OR ISOALLOLITHOCHOLIC ACID AND DEUTERATED DERIVATIVES THEREOF FOR PREVENTING AND TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES DHCR7, CYP27A1, SLC10A2 GPBAR1 27/4885EPHA2 2838/4885CASP7 523/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 GPBAR1 138/4885EPHA2 1690/4885CASP7 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.